ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1870

Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration

Pamela F. Weiss1, Timothy G. Brandon2, Amita Aggarwal3, Ruben Burgos-Vargas4, Robert Colbert5, Gerd Horneff6, Rik Joos7, Ronald Laxer8, Kirsten Minden9, Angelo Ravelli10, Nicolino Ruperto11, Judith Smith12, Matthew Stoll13, Shirley Tse14, Filip Van den Bosch15 and Raymond Naden16, 1Children's Hospital of Philadelphia, Philadelphia, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 4Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, 5Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 6Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 7Ziekenhuis Netwerk Antwerpen, Basel, Switzerland, 8The Hospital for Sick Children, Toronto, ON, Canada, 9Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 10Università degli Studi di Genova, Genoa, Italy, 11PRINTO, Istituto Giannina Gaslini, Genova, Italy, 12University of Wisconsin, Madison, WI, 13University of Alabama at Birmingham, Birmingham, AL, 14SickKids, Toronto, ON, Canada, 15Ghent University Hospital, Ghent, Belgium, 16Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand

Meeting: ACR Convergence 2020

Keywords: classification criteria, Pediatric rheumatology, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The lack of pediatric classification criteria for axial disease is a major impediment to the conduct of clinical trials for juvenile spondyloarthritis (SpA). Classification criteria for axial disease in children with SpA are being developed. The objective of this study was to identify and grade a set of items that maximizes the likelihood of accurate classification of children and adolescents with axial disease.

Methods: First, we conducted an item-generation exercise with an international group of pediatric rheumatologists to generate a comprehensive list of clinical, laboratory, and imaging features used to decide whether or not a child/adolescent has clinical evidence of axial involvement. Second, we performed a literature review to formulate a list of features used in juvenile and adult SpA clinical study inclusion criteria and adult axial SpA classification criteria. Next, we completed a grading exercise in which respondents in the item generation survey rated the features generated from the first 2 steps for specificity (-3 to +3), with anchors “much less likely to have axial disease” and “much more likely to have axial disease”, respectively. Items with a mean score of zero or close to zero and redundant items were removed. The final list of items was reviewed by a panel of juvenile SpA experts and split into “entry criteria”, which would be required for classification applicability, potential “additive criteria”, and potential “exclusion” or “negatively weighted criteria”. Additive and negatively weighted criteria were grouped into domains by an iterative process.

Results: One hundred and ninety-nine physicians from 45 countries proposed 108 items useful in the determination of axial involvement or not. Responses showed broad coverage but also high consistency. Responses were grouped into 15 domains with a range of 38-141 unique respondents noting ≥1 item in a domain. Most items were related to imaging, location of pain or stiffness, pattern of pain, genetics, range of motion, laboratory markers, and comorbidities.  Literature review did not identify any additional clinical features to include in the item reduction exercise. In the grading exercise, 87 items had a mean score of ≥1.5 and 5 items ≤1.5. The expert panel reviewed the candidate items, grouped them into 6 independent domains, and identified 2 entry criteria, 2 exclusion criteria, 23 potential additive criteria, and 4 negatively weighted criteria (Table). The expert panel also voted to align criteria within the imaging domains with definitions provided by the OMERACT Juvenile Arthritis MRI Score (JAMRIS) international Working Group (1) when possible and to exclude radiographs and spinal MRI. Final additive and negatively-weighted criteria will be determined after evaluation of the sensitivity and specificity of potential criteria in a development cohort of juvenile SpA cases.

Conclusion: The item-generation exercise, grading exercise, and expert panel’s iterative work resulted in inclusion, exclusion, candidate additive and negatively weighted criteria. Refinement and weighting of criteria as well as determination of threshold for classification will be ascertained in the next phase.

*Peripheral arthritis should be present for ≥6 weeks. ^≥4 of the following: improvement with exercise, pain at night, insidious onset, age at onset < 40 years, and no improvement with rest (3). # modified NY criteria for radiographs(4) and ASAS MRI working group definitions of active sacroiliitis (5).


Disclosure: P. Weiss, Lilly, 1, Pfizer, 1; T. Brandon, None; A. Aggarwal, None; R. Burgos-Vargas, None; R. Colbert, Eli Lilly and Company, 2, Eli Lilly and Company, 9; G. Horneff, Pfizer, 5, 8, AbbVie, 5, 8, Novartis, 5, 8, Sanofi, 5, 8; R. Joos, None; R. Laxer, Eli Lilly Canada, 1, Novartis, 1, Sanofi, 1; K. Minden, Sanofi, 1, gsk, 1, Roche, 1, Abbvie, 1, Biermann, 8, Medac, 8; A. Ravelli, AbbVie, BMS, Pfizer, Hoffman LaRoche, Novartis, Centocor, "Francesco Angelini" and Reckitt Benckiser., 1, 2; N. Ruperto, AstraZeneca-MedImmune, 5, 8, Biogen, 5, 8, Eli Lilly, 2, 5, 8, EMD Serono, 5, 8, Janssen, 2, 5, 8, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, Sobi, 2, 5, Bristol-Myers Squibb, 2, 5, 8, GlaxoSmithKline, 2, 5, 8, Roche, 2, 5, 8, AbbVie, 5, 8, Ablynx, 5, 8, Merck, 5, 8, R-Pharm, 5, Sanofi, 5, Servier, 5, Sinergie, 5, Takeda, 5, Boehringer Ingelheim, 5, 8; J. Smith, None; M. Stoll, None; S. Tse, None; F. Van den Bosch, AbbVie, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Galapagos, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Gilead, 5, Merck, 5, 8; R. Naden, ACR/EULAR, 1, 2.

To cite this abstract in AMA style:

Weiss P, Brandon T, Aggarwal A, Burgos-Vargas R, Colbert R, Horneff G, Joos R, Laxer R, Minden K, Ravelli A, Ruperto N, Smith J, Stoll M, Tse S, Van den Bosch F, Naden R. Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/development-of-candidate-criteria-for-axial-disease-in-juvenile-spondyloarthritis-an-international-collaboration/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-candidate-criteria-for-axial-disease-in-juvenile-spondyloarthritis-an-international-collaboration/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology